Backed with $500 million, a startup aims to rethink psychiatric drug development
Neumora, a roll-up of assets from several biotech firms and the drug giant Amgen, is seeking to "apply precision medicine" to CNS diseases.
Read The StoryBiotech
Inside the discoveries, personalities, and deals driving drug development. Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox. And subscribe to STAT+ to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial readouts
Inside the downfall of longevity crusader Aubrey de Grey — and the cult of personality that concealed a pattern of harassment
Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine
Vedanta touts positive new data for its C. diff microbiome therapeutic — but is it too late?
The biotech scorecard for the fourth quarter: 19 stock-moving events to watch
All Coverage
advertisement
